New Guidelines mandating neuromuscular monitoring of patients and the availability of monitoring in every operating room
News: Uppsala, on 22 May 2021. Senzime today announces that the Association of Anaesthetists in the UK and Ireland has issued new standards for neuromuscular monitoring stating that Quantitative neuromuscular monitoring is essential and should be available in every operating theatre/site in the UK and Ireland.
Patient complications after anesthesia remains an issue and harmful consequences of inadequate recovery include generalized muscle weakness and delayed recovery; risk of aspiration; postoperative pulmonary complications and death.
The new guideline states that Quantitative neuromuscular monitoring should be used whenever neuromuscular blocking (NMB) drugs are administered, throughout all phases of anesthesia from before initiation of neuromuscular blockade until recovery of the train-of-four ratio to > 0.9 has been confirmed.
The Guideline also states, that when the hand is inaccessible during surgery the use of a device where you can tuck the arm like for example electromyography (EMG) is suggested. This was also reinforced during a webinar held by the association today confirming that only EMG monitoring will allow precise values due to the overestimation of recovery by other techniques.
The number of surgeries/ operating rooms in the United Kingdom and Ireland that are affected by the new guidelines is estimated to amount to more than 10 million surgeries annually based on over 3,000 operating rooms.
“This is another great recognition of the critical complications these procedures might encounter if a quantitative monitor is not used. Senzimes TetraGraph system is developed to prevent the preventable, monitoring every case in every place is indeed a huge step for enhancing patient safety”, says Pia Renaudin, CEO of Senzime.
TetraGraph is a unique Quantitative digital system based on electromyography that measures the presence and depth of neuromuscular blockade to enable the doctor to determine the correct drug dosage and assess when the patient is ready to breathe on their own without the risk of complications. Due to its technical versatility, the TetraGraph can be used for all types of surgeries including when the arm needs to be tucked, and in any site since it can follow the patient outside the operating theatre.
Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org is Certified Adviser for Senzime. www.senzime.com